Arix Bioscience

Summary

In 2015 was created Arix Bioscience, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the London. The company was established in Europe in United Kingdom.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Arix Bioscience, startups are often financed by UBS Asset Management, SV Health Investors, OrbiMed. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Lundbeckfonden Ventures, Sofinnova Investments. In the next rounds fund is usually obtained by iBank, Woodford Investment Management, UCLB.

Besides them, we counted 5 critical employees of this fund in our database.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Collaboration, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Atox Bio, VelosBio, Imara. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2018. This Arix Bioscience works on 2 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually. Speaking about the real fund results, this Corporate Investor is 40 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund.